TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q4 2023

Tonix Pharmaceuticals (NASDAQ:TNXP) just reported results for the fourth quarter of 2023.

• Tonix Pharmaceuticals reported earnings per share of -86 cents. This was above the analyst estimate for EPS of -$1.64.
• The company reported revenue of $3.78 million.
• This was 1.33% worse than the analyst estimate for revenue of $3.83 million.

InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected].

More From InvestorPlace

• The #1 AI Investment Might Be This Company You’ve Never Heard Of
• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• It doesn’t matter if you have $500 or $5 million. Do this now.

The post TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q4 2023 appeared first on InvestorPlace.